<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38491425</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Circulating vaccine derived polio virus type 2 outbreak and response in Yemen, 2021-2022, a retrospective descriptive analysis.</ArticleTitle><Pagination><StartPage>321</StartPage><MedlinePgn>321</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">321</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-024-09215-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The outbreaks of circulating Vaccine Derived Polio Viruses (cVDPVs) have emerged as a major challenge for the final stage of polio eradication. In Yemen, an explosive outbreak of cVDPV2 was reported from August 2021 to December 2022. This study aims to compare the patterns of cVDPV2 outbreak, response measures taken by health authorities, and impacts in southern and northern governorates.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A retrospective descriptive study of confirmed cases of VDPV2 was performed. The data related to cVDPV2 as well as stool specimens and environmental samples that were shipped to WHO-accredited labs were collected by staff of surveillance. Frequencies and percentages were used to characterize and compare the confirmed cases from the southern and northern governorates. The average delayed time as a difference in days between the date of sample collection and lab confirmation was calculated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The cVDPV2 was isolated from 227 AFP cases reported from 19/23 Yemeni governorates and from 83% (39/47) of environmental samples with an average of 7 months delayed from sample collection. However, the non-polio AFP (NPAFP) and adequate stool specimen rates in the north were 6.7 and 87% compared to 6.4 and 87% in the south, 86% (195) and 14%(32) out of the total 227 confirmed cases were detected from northern and southern governorates, respectively. The first and second cases of genetically linked isolates experienced paralysis onset on 30 August and 1st September 2021. They respectively were from Taiz and Marib governorates ruled by southern authorities that started vaccination campaigns as a response in February 2022. Thus, in contrast to 2021, the detected cases in 2022 from the total cases detected in the south were lower accounting for 22% (7 of 32) of compared to 79% (155 of 195) of the total cases the north.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A new emerging cVDPV2 was confirmed in Yemen. The result of this study highlighted the impact of vaccination campaigns in containing the cVDPV2 outbreak. Maintaining a high level of immunization coverage and switching to nOPV2 instead of tOPV and mOPV2 in campaigns are recommended and environmental surveillance should be expanded in such a risky country.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Al-Qassimi</LastName><ForeName>Mutahar Ahmed</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>National Polio surveillance coordinator, Yemen Ministry of Public Health and Population, Sana'a, Yemen. maque55@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Amad</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Community Medicine, Faculty of Medicine and Health Sciences, Sana'a University, Sana'a, Yemen.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Dar</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Community Medicine, Faculty of Medicine and Health Sciences, Sana'a University, Sana'a, Yemen.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Sakaf</LastName><ForeName>Ehab</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>General Director for Diseases Control and Surveillance, Yemen Ministry of Public Health and Population, Sana'a, Yemen.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Hadad</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, Sana'a university, Sana'a, Yemen.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yemen National Certification of polio eradication Committee chairperson, Sana'a, Yemen.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raja'a</LastName><ForeName>Yahia Ahmed</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, Sana'a university, Sana'a, Yemen.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000509">alpha-Fetoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015006" MajorTopicYN="N" Type="Geographic">Yemen</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000509" MajorTopicYN="N">alpha-Fetoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">2022</Keyword><Keyword MajorTopicYN="N">Circulating Vaccine Derived Polio Virus Type 2</Keyword><Keyword MajorTopicYN="N">Outbreak</Keyword><Keyword MajorTopicYN="N">Yemen</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>16</Day><Hour>21</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>16</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38491425</ArticleId><ArticleId IdType="pmc">PMC10943856</ArticleId><ArticleId IdType="doi">10.1186/s12879-024-09215-1</ArticleId><ArticleId IdType="pii">10.1186/s12879-024-09215-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Agol VI. Vaccine-derived polioviruses. Biologicals. 2006;34(2):103–8. doi: 10.1016/j.biologicals.2006.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biologicals.2006.02.007</ArticleId><ArticleId IdType="pubmed">16650771</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis. 2014;210(suppl1):S283–93. doi: 10.1093/infdis/jiu295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu295</ArticleId><ArticleId IdType="pubmed">25316847</ArticleId></ArticleIdList></Reference><Reference><Citation>GPEI. GPEI-Circulating vaccine-derived poliovirus. 2023.</Citation></Reference><Reference><Citation>Bigouette JP. Update on vaccine-derived Poliovirus Outbreaks — Worldwide, January 2021–December 2022. MMWR Morb Mortal Wkly Rep. 2023;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10078846</ArticleId><ArticleId IdType="pubmed">37022974</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin GR, Goel AK, Mach O, Tallis G, Ahmed JA, O’Reilly KM, et al. Epidemiology of type 2 vaccine-derived poliovirus outbreaks between 2016 and 2020. Vaccine. 2023;41:A19–24. doi: 10.1016/j.vaccine.2022.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.08.008</ArticleId><ArticleId IdType="pubmed">36008232</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaawal A. An outbreak of circulating vaccine derived poliovirus in Yemen, 2011–2012. Int J Infect Dis. 2014;21:457. doi: 10.1016/j.ijid.2014.03.1363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2014.03.1363</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorba J. Update on vaccine-derived Polioviruses — Worldwide, January 2016–June 2017. MMWR Morb Mortal Wkly Rep. 2017;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5689216</ArticleId><ArticleId IdType="pubmed">29095803</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Qassimi MA, Al Amad M, Anam L, Almoayed K, Al-Dar A, Ezzadeen F. Circulating vaccine derived Polio virus type 1 outbreak, Saadah governorate, Yemen, 2020. BMC Infect Dis. 2022;22(1):1–11. doi: 10.1186/s12879-022-07397-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07397-0</ArticleId><ArticleId IdType="pmc">PMC9052627</ArticleId><ArticleId IdType="pubmed">35488227</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohanty A, Rohilla R, Zaman K, Hada V, Dhakal S, Shah A, et al. Vaccine derived Poliovirus (VDPV) Le Infezioni in Medicina. 2023;31(2):174–85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10241397</ArticleId><ArticleId IdType="pubmed">37283637</ArticleId></ArticleIdList></Reference><Reference><Citation>Lackner H. Fragmentation nation: how europeans can help end the conflict in Yemen. ECFR. 2022.</Citation></Reference><Reference><Citation>Torbosh A, Al Amad MA, Al Serouri A, Khader Y. The impact of War in Yemen on Immunization Coverage of children under one year of age: descriptive study. JMIR Public Health Surveillance. 2019;5(4):e14461. doi: 10.2196/14461.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/14461</ArticleId><ArticleId IdType="pmc">PMC6913770</ArticleId><ArticleId IdType="pubmed">31647465</ArticleId></ArticleIdList></Reference><Reference><Citation>PATH. New tool detects poliovirus hiding in the environment. 2017.</Citation></Reference><Reference><Citation>Fagnant-Sperati CS, Ren Y, Zhou NA. Validation of the bag-mediated filtration system for environmental surveillance of poliovirus in Nairobi. Kenya. 2021;130(3):971–81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7854911</ArticleId><ArticleId IdType="pubmed">32743931</ArticleId></ArticleIdList></Reference><Reference><Citation>GPEI. GPEI-Statement on stopping transmission of VDPV2 in Yemen’s northern governorates and in Somalia. 2023.</Citation></Reference><Reference><Citation>Grassly NC. Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis. J Infect Dis. 2014;210(Suppl):1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4197908</ArticleId><ArticleId IdType="pubmed">24634499</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Ethiopia launches the 1st round synchronized mOPV2 campaign WHO Regional Office for Africa: WHO. 2018 [updated 2018/08/25/; cited 10 July 2018].</Citation></Reference><Reference><Citation>Cooper LV, Bandyopadhyay AS, Gumede N, Mach O, Mkanda P, Ndoutabé M, et al. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa. Lancet Infect Dis. 2022;22(2):284–94. doi: 10.1016/S1473-3099(21)00453-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00453-9</ArticleId><ArticleId IdType="pmc">PMC8799632</ArticleId><ArticleId IdType="pubmed">34648733</ArticleId></ArticleIdList></Reference><Reference><Citation>Afsar A, Mallya A, Mohammed AAG, Anand S, Diomande VKF, Maufras du Châtellier G, et al. Monovalent type 2 OPV (mOPV2) management in the field: interventions and lessons learned. Vaccine. 2023;41:A79–84. doi: 10.1016/j.vaccine.2022.12.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.12.033</ArticleId><ArticleId IdType="pubmed">36642630</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray EJ, Cooper LV, Bandyopadhyay AS, Blake IM, Grassly NC. The origins and Risk factors for Serotype-2 vaccine-derived Poliovirus emergences in Africa during 2016–2019. J Infect Dis. 2023:jiad004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10304761</ArticleId><ArticleId IdType="pubmed">36630295</ArticleId></ArticleIdList></Reference><Reference><Citation>Alipon SB, Takashima Y, Avagyan T, Grabovac V, Sucaldito N. Emergence of vaccine-derived poliovirus type 2 after using monovalent type 2 oral poliovirus vaccine in an outbreak response, Philippines. Western Pacific surveillance and response journal. WPSAR. 2022;13(2):1–7. doi: 10.5365/wpsar.2022.13.2.904.</Citation><ArticleIdList><ArticleId IdType="doi">10.5365/wpsar.2022.13.2.904</ArticleId><ArticleId IdType="pmc">PMC9580276</ArticleId><ArticleId IdType="pubmed">36276175</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagnant CS, Sánchez-Gonzalez LM, Zhou NA, Falman JC, Eisenstein M, Guelig D, et al. Improvement of the bag-mediated Filtration System for Sampling Wastewater and Wastewater-Impacted Waters. Food Environ Virol. 2018;10(1):72–82. doi: 10.1007/s12560-017-9311-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12560-017-9311-7</ArticleId><ArticleId IdType="pmc">PMC5823955</ArticleId><ArticleId IdType="pubmed">28674934</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper LV, Erbeto TB, Danzomo AA, Abdullahi HW, Boateng K, Adamu US et al. Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 Poliomyelitis in Nigeria between 2017 and 2022: a case-control study. Lancet Infect Dis. 2024;0(0).</Citation><ArticleIdList><ArticleId IdType="pubmed">38246190</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. Polio Vaccine Effectiveness and Duration of Protection| CDC. 2022 [updated 2022/08/26/]. Available from: https://www.cdc.gov/vaccines/vpd/polio/hcp/effectiveness-duration-protection.html.</Citation></Reference><Reference><Citation>Alleman MM. Update on vaccine-derived Poliovirus Outbreaks — Worldwide, January 2020–June 2021. MMWR Morb Mortal Wkly Rep. 2021;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8659190</ArticleId><ArticleId IdType="pubmed">34882653</ArticleId></ArticleIdList></Reference><Reference><Citation>Deressa W, Kayembe P, Neel AH, Mafuta E, Seme A, Alonge O. Lessons learned from the polio eradication initiative in the Democratic Republic of Congo and Ethiopia: analysis of implementation barriers and strategies. BMC Public Health. 2020;20(4):1807. doi: 10.1186/s12889-020-09879-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-020-09879-9</ArticleId><ArticleId IdType="pmc">PMC7747367</ArticleId><ArticleId IdType="pubmed">33339529</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidanne L, Bisrat F, Mohammed M, Deyessa N. Curbing an outbreak of circulating vaccine derived poliovirus type 2 in Dollo Zone, Somali Region, Ethiopia: response to outbreak. Pan Afr Med J. 2022;42:46. doi: 10.11604/pamj.2022.42.46.32856.</Citation><ArticleIdList><ArticleId IdType="doi">10.11604/pamj.2022.42.46.32856</ArticleId><ArticleId IdType="pmc">PMC9338724</ArticleId><ArticleId IdType="pubmed">35949467</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>